PILL Direxion Daily Pharmaceutical & Medical Bull 3X Shares
- 6.550
- +0.140+2.18%
Stocks Most Shunned by Hedge Funds and Mutual Funds
Emerging and Chinese Pharmas Playing Greater Role in Oncology Drug Development
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
Corbus Outlines Phase 1 Results From ADC Trial for Bladder, Cervical Cancers
FDA Oncology Chief Says International Clinical Trials Should Be Priority
Summit Lead Asset Approved in China for Lung Cancer
Immunocore Touts Updated Phase 1 Results for Melanoma Asset Brenetafusp
Novartis Boasts Scemblix Beats Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Moderna Wins FDA Approval for RSV Vaccine
Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry o
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company's stock closed 272.1% higher at $10.92 on Thursday.Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced
Dow futures rise positive response to PCE deflator Dell falls drastically after hours = US stocks
In addition to Dow futures rebounding in the US stock index futures market, S&P 500 and NASDAQ 100 are also rebounding. The US stock market has shown a positive response in response to the April PCE deflator that was announced earlier.
Summit -25%, Pares Gains as 'China-only' Trial Beats Merck's Keytruda
How To Earn $500 A Month From Pfizer Stock
Shares of Pfizer Inc. (NYSE:PFE) closed higher during Thursday's session, with the company's stock adding around 10% over the past month.Pfizer recently launched a multi-year cost reduction initiative
Dividend Roundup: Meta Platforms, Merck, Cigna, Halliburton, and More
Pfizer Gene Therapy for Haemophilia B Therapy Endorsed in EU
Smart Money Is Betting Big In MRK Options
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE:MRK).And retail traders should know.We noticed this today when the trades showed up on publicly available options
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY
Summit Therapeutics Announces Phase III Trial HARMONi-2 Meets Primary Endpoint Of Progression-Free Survival For Ivonescimab In Advanced NSCLC With PD-L1 Expression
Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLCMonotherapy Ivonescimab Achieved Clinically Mean
Pfizer's Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bearish stance on Pfizer (NYSE:PFE).And retail traders should know.We noticed this today when the positions showed up on publicly available options